Your browser doesn't support javascript.
The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19.
Pereira, Marcos; Paixão, Enny; Trajman, Anete; de Souza, Ramon Andrade; da Natividade, Marcio Santos; Pescarini, Julia M; Pereira, Susan Martins; Barreto, Florisneide Rodrigues; Ximenes, Ricardo; Dalcomo, Margareth; Ichihara, Maria Yury; Nunes, Ceuci; Barral-Netto, Manoel; Barreto, Maurício L.
  • Pereira M; Institute of Collective Health, Federal University of Bahia, Salvador, Brazil. pereira.santosm@yahoo.com.
  • Paixão E; Center for Data and Knowledge Integration for Health (CIDACS), Fiocruz, Salvador, Brazil.
  • Trajman A; Faculty of Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
  • de Souza RA; Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
  • da Natividade MS; Institute of Collective Health, Federal University of Bahia, Salvador, Brazil.
  • Pescarini JM; Institute of Collective Health, Federal University of Bahia, Salvador, Brazil.
  • Pereira SM; Center for Data and Knowledge Integration for Health (CIDACS), Fiocruz, Salvador, Brazil.
  • Barreto FR; Institute of Collective Health, Federal University of Bahia, Salvador, Brazil.
  • Ximenes R; Institute of Collective Health, Federal University of Bahia, Salvador, Brazil.
  • Dalcomo M; Departamento de Medicina Tropical, Universidade Federal de Pernambuco, Recife, Brazil.
  • Ichihara MY; Centro de Referência Hélio Fraga, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
  • Nunes C; Center for Data and Knowledge Integration for Health (CIDACS), Fiocruz, Salvador, Brazil.
  • Barral-Netto M; Hospital Couto Maia, Secretaria Estadual de Saúde da Bahia, Salvador, Brazil.
  • Barreto ML; Instituto Gonçalo Moniz - Fundação Oswaldo Cruz (Fiocruz), Salvador, Brazil.
Respir Res ; 21(1): 178, 2020 Jul 11.
Article in English | MEDLINE | ID: covidwho-639735
ABSTRACT
Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conducted in different settings.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Quality Control / BCG Vaccine / Coronavirus Infections / Pandemics Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Female / Humans / Male Language: English Journal: Respir Res Year: 2020 Document Type: Article Affiliation country: S12931-020-01439-4

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Quality Control / BCG Vaccine / Coronavirus Infections / Pandemics Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Female / Humans / Male Language: English Journal: Respir Res Year: 2020 Document Type: Article Affiliation country: S12931-020-01439-4